The existing and current efforts are substantial, no doubt, but in a relative sense, AMR is neglected. Relative to the global burden of disease and expenditure on R&D, or relative to the projected costs of mitigation.

I think that the proposal identifies some interesting potential areas of work. A couple of unsolicited thoughts:

• In addition to developing generalized plans and associated SOPs, it may be important in phase I to develop assessment tools to identify gaps, and map the existing industry and FDA minimum standards and practices (I think this is referred to within the theory of change)
• Globally-relevant partner stakeholders that immediately come to mind are IFPMA and PhRMA 
• Finding opportunities to improve FDA regulatory avenues is another downstream piece of work
• Is the scope of work, at least initially, focused on US and European pharmaceutical infrastructure?